372 related articles for article (PubMed ID: 9416838)
21. p53 gene mutations in breast cancers in midwestern US women: null as well as missense-type mutations are associated with poor prognosis.
Saitoh S; Cunningham J; De Vries EM; McGovern RM; Schroeder JJ; Hartmann A; Blaszyk H; Wold LE; Schaid D; Sommer SS
Oncogene; 1994 Oct; 9(10):2869-75. PubMed ID: 8084591
[TBL] [Abstract][Full Text] [Related]
22. p53 tumor suppressor gene mutation in early esophageal precancerous lesions and carcinoma among high-risk populations in Henan, China.
Gao H; Wang LD; Zhou Q; Hong JY; Huang TY; Yang CS
Cancer Res; 1994 Aug; 54(16):4342-6. PubMed ID: 8044781
[TBL] [Abstract][Full Text] [Related]
23. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group.
Chiba I; Takahashi T; Nau MM; D'Amico D; Curiel DT; Mitsudomi T; Buchhagen DL; Carbone D; Piantadosi S; Koga H
Oncogene; 1990 Oct; 5(10):1603-10. PubMed ID: 1979160
[TBL] [Abstract][Full Text] [Related]
24. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of FHIT, CTNNB1, and MUC1 expression in non-small cell lung cancer.
Woenckhaus M; Merk J; Stoehr R; Schaeper F; Gaumann A; Wiebe K; Hartmann A; Hofstaedter F; Dietmaier W
Hum Pathol; 2008 Jan; 39(1):126-36. PubMed ID: 17949785
[TBL] [Abstract][Full Text] [Related]
26. Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history.
Mounawar M; Mukeria A; Le Calvez F; Hung RJ; Renard H; Cortot A; Bollart C; Zaridze D; Brennan P; Boffetta P; Brambilla E; Hainaut P
Cancer Res; 2007 Jun; 67(12):5667-72. PubMed ID: 17575133
[TBL] [Abstract][Full Text] [Related]
27. Association of the DNA repair gene XPD Asp312Asn polymorphism with p53 gene mutations in tobacco-related non-small cell lung cancer.
Gao WM; Romkes M; Day RD; Siegfried JM; Luketich JD; Mady HH; Melhem MF; Keohavong P
Carcinogenesis; 2003 Oct; 24(10):1671-6. PubMed ID: 12844488
[TBL] [Abstract][Full Text] [Related]
28. [Molecular analysis of tumor suppressor genes p16INK4 and TP53 of osteosarcomas in Spanish children].
Patiño García A; Sierrasesúmaga Ariznabarreta L
An Esp Pediatr; 1997 Nov; 47(5):478-82. PubMed ID: 9586287
[TBL] [Abstract][Full Text] [Related]
29. Genetic and epigenetic screening for gene alterations of the chromatin-remodeling factor, SMARCA4/BRG1, in lung tumors.
Medina PP; Carretero J; Fraga MF; Esteller M; Sidransky D; Sanchez-Cespedes M
Genes Chromosomes Cancer; 2004 Oct; 41(2):170-7. PubMed ID: 15287030
[TBL] [Abstract][Full Text] [Related]
30. Carcinogen exposure, p53 alteration, and K-ras mutation in synchronous multiple primary lung carcinoma.
Wang X; Christiani DC; Mark EJ; Nelson H; Wiencke JK; Gunn L; Wain JC; Kelsey KT
Cancer; 1999 Apr; 85(8):1734-9. PubMed ID: 10223567
[TBL] [Abstract][Full Text] [Related]
31. Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women.
Gealy R; Zhang L; Siegfried JM; Luketich JD; Keohavong P
Cancer Epidemiol Biomarkers Prev; 1999 Apr; 8(4 Pt 1):297-302. PubMed ID: 10207632
[TBL] [Abstract][Full Text] [Related]
32. [Correlation between p53 gene mutation and protein expression in 30 cases of human lung cancer].
Zhang J; Zheng J; Fang W
Zhonghua Yi Xue Za Zhi; 1998 Nov; 78(11):846-9. PubMed ID: 11038779
[TBL] [Abstract][Full Text] [Related]
33. A novel molecular staging protocol for non-small cell lung cancer.
Miyake M; Adachi M; Huang C; Higashiyama M; Kodama K; Taki T
Oncogene; 1999 Apr; 18(14):2397-404. PubMed ID: 10327061
[TBL] [Abstract][Full Text] [Related]
34. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.
Chou TY; Chiu CH; Li LH; Hsiao CY; Tzen CY; Chang KT; Chen YM; Perng RP; Tsai SF; Tsai CM
Clin Cancer Res; 2005 May; 11(10):3750-7. PubMed ID: 15897572
[TBL] [Abstract][Full Text] [Related]
35. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.
De Petris L; Orre LM; Kanter L; Pernemalm M; Koyi H; Lewensohn R; Lehtiö J
Lung Cancer; 2009 Mar; 63(3):410-7. PubMed ID: 18620780
[TBL] [Abstract][Full Text] [Related]
36. p53 mutation is infrequent in clear cell carcinoma of the ovary.
Ho ES; Lai CR; Hsieh YT; Chen JT; Lin AJ; Hung MH; Liu FS
Gynecol Oncol; 2001 Feb; 80(2):189-93. PubMed ID: 11161858
[TBL] [Abstract][Full Text] [Related]
37. Variation of p53 mutational spectra between carcinoma of the upper and lower respiratory tract.
Law JC; Whiteside TL; Gollin SM; Weissfeld J; El-Ashmawy L; Srivastava S; Landreneau RJ; Johnson JT; Ferrell RE
Clin Cancer Res; 1995 Jul; 1(7):763-8. PubMed ID: 9816043
[TBL] [Abstract][Full Text] [Related]
38. [Analysis of mutation types of p53 gene and possible carcinogenic factors in lung cancer].
Gao ZQ; Gao Z; Zhang X
Zhonghua Yu Fang Yi Xue Za Zhi; 1997 Mar; 31(2):88-91. PubMed ID: 9812619
[TBL] [Abstract][Full Text] [Related]
39. Frequency of TP53 mutations in relation to Arg72Pro genotypes in non small cell lung cancer.
Lind H; Ekstrøm PO; Ryberg D; Skaug V; Andreassen T; Stangeland L; Haugen A; Zienolddiny S
Cancer Epidemiol Biomarkers Prev; 2007 Oct; 16(10):2077-81. PubMed ID: 17932356
[TBL] [Abstract][Full Text] [Related]
40. KLF6: mutational analysis and effect on cancer cell proliferation.
Yin D; Komatsu N; Miller CW; Chumakov AM; Marschesky A; McKenna R; Black KL; Koeffler HP
Int J Oncol; 2007 Jan; 30(1):65-72. PubMed ID: 17143513
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
